9-ING-41 in Pediatric Patients With Refractory Malignancies.

Conditions:   Refractory Cancer;   Refractory Neoplasm;   Cancer Pediatric;   Refractory Tumor;   Pediatric Cancer;   Pediatric Brain Tumor;   Neuroblastoma;   Neuroblastoma Recurrent;   Pediatric Lymphoma;   Pediatric Meningioma Interventions:   Drug: 9-ING-41;   Drug: Irinotecan Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: Available online 22 February 2020Source: Reproductive BioMedicine OnlineAuthor(s): Andrea BUSNELLI, Amerigo VITAGLIANO, Laura MENSI, Stefano ACERBONI, Alessandro BULFONI, Francesca FILIPPI, Edgardo SOMIGLIANAAbstractSeveral epidemiological studies investigated the effects of cancer therapies on fertility. However, conflicting data have been reported.The present systematic review and meta-analysis aims to determine the chances of childbirth in women survived from different types of cancer.We systematically searched Pubmed, MEDLINE, Embase and Scopus, from database inception to July 17, 2019, for published ...
Source: Reproductive BioMedicine Online - Category: Reproduction Medicine Source Type: research
Conditions:   Refractory Cancer;   Refractory Neoplasm;   Cancer Pediatric;   Refractory Tumor;   Pediatric Cancer;   Pediatric Brain Tumor;   Neuroblastoma;   Neuroblastoma Recurrent;   Pediatric Lymphoma;   Pediatric Meningioma Interventions:   Drug: 9-ING-41;   Drug: Irinotecan Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
SummaryAnaplastic lymphoma kinase (ALK), which belongs to the insulin receptor tyrosine kinase superfamily, plays an important role in nervous system development. Due to chromosomal translocations, point mutations, and gene amplification, constitutively activated ALK has been implicated in a variety of human cancers, including anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer, and neuroblastoma. We evaluated the anti-cancer activity of the ALK inhibitor KRCA-0008 using ALCL cell lines that express NPM (nucleophosmin)-ALK. KRCA-0008 strongly suppressed the proliferation and survival of NPM-ALK-positive ALCL ...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Albert Rizvanov Chimeric antigen receptor (CAR) immunotherapy is one of the most promising modern approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah® and Yescarta®, have been approved by the Food and Drug Administration (FDA) for the treatment of lymphoblastic leukemia and B-cell lymphoma. Administration of CAR T-cells to control solid tumors has long been envisaged as one of the most difficult therapeutic tasks. The first two clinical trials conducted in sarcoma and neuroblastoma patients showed clinical benefits of CAR T-cells, yet multiple obstacles still hold us ba...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 17 December 2019Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Ivo ŠteinerAbstractThe aim of this paper is dual - to review the relevant literature on pathology of radiation induced heart disease (RIHD), and to present an illustrative case of our own. Therapeutic ionizing radiation, such as that used in the treatment of Hodgkin´s lymphoma and cancers of left breast, lungs, esophagus, and thymus, can cause cardiac damage that may take several years to manifest.The spectrum of RIHD is broad and includes [1] pericarditis and pericardial effusion; [2] endocardi...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Abstract Over the past decades, studies of phytochemicals as modifiers of radiotherapeutic efficacy have become increasingly popular to improve the treatment outcome of human malignancies. In the current comprehensive review article, radiosensitizing effects of curcumin, a yellow-colored polyphenolic constituent of turmeric, in various preclinical cancer models, both In Vitro and In Vivo, are presented. Attenuation of radioadaptation and augmentation of irradiation-induced cancer cell killing are achieved through multifaceted action of curcumin on suppression of prosurvival and antiapoptotic factors. Mos...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
Molecular alterations in malignant disease result in the expression or upregulations of various targets that can be used for imaging and treatment with radiopharmaceuticals. This theranostic principle has acquired greater importance in personalized medicine in recent years, particularly in oncology, where advanced tumors can be treated effectively with low side effects. Since the pioneering use of 131I in differentiated thyroid cancer in the 1940s, remarkable achievements in nuclear medicine endoradiotherapy have been demonstrated, mainly in the treatment of neuroendocrine neoplasms by using 177Lu-labeled somatostatin anal...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Supplement Source Type: research
This article summarizes the recent advances in research on the multifarious pharmacological effects of A. camphorata. The mushroom exhibits anticancer activity toward a large variety of cancers including breast, cervical, ovarian, prostate, bladder, colorectal, pancreatic, liver, and lung cancers; melanoma; leukemia; lymphoma; neuroblastoma; and glioblastoma. Other activities encompass antiinflammatory, antiatopic dermatitis, anticachexia, immunoregulatory, antiobesity, antidiabetic, antihyperlipidemic, antiatherosclerotic, antihypertensive, antiplatelet, antioxidative, antiphotodamaging, hepatoprotective, renoprotective, ...
Source: Applied Microbiology and Biotechnology - Category: Microbiology Authors: Tags: Appl Microbiol Biotechnol Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Lymphoma | Men | Neuroblastoma | Neurology | Pediatrics | Research